DSKYF
Daiichi Sankyo Company, Limited
Set alert
17.26 USD +0.29 +1.71%
18.70 Day range 18.70
13.85 52-week range 25.75
- YTD
- -19.72%
- 1 year
- -31.04%
- Open
- 18.70
- Prev close
- 16.97
- Mkt cap
- 31.41B
- Vol
- 5
- Avg vol
- 3.98K
- EPS
- 0.86
- P/E
- 20.07
More statistics
- Low
- 18.70
- High
- 18.70
- Earnings
- Nov 4, 2026
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.241.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.241 | — | — | — |
| Jul 31, 2026 | Jun 30, 2026 | 0.2521 | 0.2319 | -0.02 | -8.01% |
| May 11, 2026 | Mar 31, 2026 | 0.3304 | 0.1455 | -0.18 | -55.96% |
| Jan 29, 2026 | Dec 31, 2025 | 0.2498 | 0.2986 | +0.05 | +19.54% |
| Oct 31, 2025 | Sep 30, 2025 | 0.303 | 0.1658 | -0.14 | -45.28% |
| Jul 31, 2025 | Jun 30, 2025 | 0.2374 | 0.3194 | +0.08 | +34.54% |
News
- Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
- Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union
- Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1
- Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO
- AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
- Merck, Daiichi Sankyo withdraw US application for lung cancer drug
- Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization
- Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results
- Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript
- Daiichi Sankyo Company, Limited (DSKYF) Q1 FY2025 Earnings Call Transcript
Your note
Sign in to keep a note on DSKYF — it syncs with the Stock Master app.